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AbstrAct
Introduction This prospective observational study 
sought to establish the glycemic, physiological and dietary 
demands of strenuous exercise training as part of a 9- day 
performance camp in a professional cycling team with type 
1 diabetes (T1D).
Research design and methods Sixteen male 
professional cyclists with T1D on multiple daily injections 
(age: 27±4 years; duration of T1D: 11±5 years; body 
mass index: 22±2 kg/m2; glycated hemoglobin: 7%±1% 
(50±6 mmol/mol); maximum rate of oxygen consumption: 
73±4 mL/kg/min) performed road cycle sessions (50%–
90% of the anaerobic threshold, duration 1–6 hours) over 
9 consecutive days. Glycemic (Dexcom G6), nutrition and 
physiological data were collected throughout. Glycemic 
data were stratified into predefined glycemic ranges and 
mapped alongside exercise physiology and nutritional 
parameters, as well as split into daytime and night- time 
phases for comparative analysis. Data were assessed by 
means of analysis of variance and paired t- tests. A p value 
of ≤0.05 (two- tailed) was statistically significant.
Results Higher levels of antecedent hypoglycemia in the 
nocturnal hours were associated with greater time spent 
in next- day hypoglycemia overall (p=0.003) and during 
exercise (p=0.019). Occurrence of nocturnal hypoglycemia 
was associated with over three times the risk of next- day 
hypoglycemia (p<0.001) and a twofold risk of low glucose 
during cycling (p<0.001). Moreover, there was trend for a 
greater amount of time spent in mild hypoglycemia during 
the night compared with daytime hours (p=0.080).
Conclusion The higher prevalence of nocturnal 
hypoglycemia was associated with an increased risk 
of next- day hypoglycemia, which extended to cycle 
training sessions. These data highlight the potential 
need for additional prebed carbohydrates and/or insulin 
dose reduction strategies around exercise training in 
professional cyclists with T1D.
Trial registration number DRKS00019923.
InTRoduCTIon
Public health, clinical consensus and diabetes 
organizations advocate regular physical exer-
cise as an important non- pharmacological 
therapy for people with type 1 diabetes 
(T1D). Current recommendations suggest 
adults attain at least 150 min per week of 
moderate- to- vigorous intensity activity and 
muscle strengthening exercises for mainte-
nance of general health.1 Yet a number of 
individuals with T1D go well beyond these 
significance of this study
What is already known about this subject?
 ► Although the physiological needs and/or demands of 
endurance exercise events have been documented 
within the literature, we know less about the real- 
time glycemic responses to performance and the 
consequential impact they may have on postexer-
cise and nocturnal glucose trends in professional 
athletes with type 1 diabetes.
What are the new findings?
 ► This study demonstrates a higher prevalence of 
nocturnal hypoglycemia in athletes undertaking dai-
ly, strenuous exercise sessions as part of a 9- day 
training block.
 ► Occurrence of night- time hypoglycemia was associ-
ated with over three times the risk of next- day hy-
poglycemia and a twofold risk of low glucose during 
cycling.
How might these results change the focus of 
research or clinical practice?
 ► These findings highlight the need for additional 
prebed carbohydrates and/or insulin dose reduction 
strategies around physical exercise training so as to 
minimize potential aberrations in glucose throughout 
the nocturnal period.
 ► The data collected as part of this study helped to 
provide a foundation for the development of indi-
vidualized nutritional, physiological and therapeutic 
strategies that may assist in improving exercise per-
formance parameters through glycemic optimization 
in elite cyclists with type 1 diabetes.
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Table 1 Anthropometric and diabetes characteristics of all 
participants (N=16)
Characteristics Mean±SD
Age (years) 27±4
Duration since diagnosis (years) 11±5
Height (m) 1.76±0.07
Body mass (kg) 67±6
BMI (kg/m2) 22±1
HbA1c (%) 6.8±0.6
HbA1c (mmol/mol) 50.3±6.2
Hb (g/dL) 150±70
HCt (%) 42.2±1.6
HRmax (bpm) 189±10
Pmax (W) 395±46
 V˙ O2max (L/min) 4.9±0.4
 V˙ O2max (mL O2/kg/min) 73.1±3.8
 V˙ E max (L/min) 177±25
Cardiopulmonary responses to incremental cycle test (n=15, 
mean±SD).
BMI, body mass index; bpm, beats per minute; Hb, hemoglobin; 
HbA1c, glycated hemoglobin; HCt, hematocrit; HRmax, maximum 
heart rate; Pmax, maximum power; VEmax, ventilatory maximum; 
VO2max, maximum rate of oxygen consumption.
minimum guidelines. Indeed, within the current research 
literature base there exist several examples of extreme 
exercise completion in people with T1D, including half 
marathons (21.1 km2), marathons (42.2 km3–6), ultramar-
athons (~133 km7), mountain ultramarathons (82 km8), 
relay ultramarathons (65–84.5 km per athlete over 3 
days9), multiday marathon walks (42 km each day for 
5 days10), Ironman events (3.8 km swim, 180 km cycle, 
42.2 km run11), Ultraman (3- day, multistage ultraendur-
ance triathlons: 10 km swim, 144.8 km bike (day 1), 
275.4 km bike (day 2), and 84.4 km run (day 3)12), ultra-
marathon (161 km cycle and 161 km run13), multiday 
cycling events (15- day, 2300 km cycling14) and cross- 
country ski events (75 km over 7+ hours15). However, in 
such extreme exercises, frequent blood glucose moni-
toring is advised to minimize dysglycemia and assure 
safe participation. Notably, endurance athletes with T1D 
report a greater occurrence of hypoglycemia compared 
with their non- endurance sporting counterparts.16 As 
such, these athletes often require greater diligence to 
glucose management strategies that emphasize nutri-
tional intake and insulin adjustment. Collectively, the 
complexity of sport and its characteristics, alongside the 
pathological heterogeneity of T1D, may explain the lack 
of athlete adherence to conventional glucose manage-
ment recommendations around competitive exercise.17 
Furthermore, the discomfort associated with frequent 
blood sampling during exercise may potentially occlude 
the true extent of exercise- induced dysglycemia. Hence, 
technological advances in continuous glucose monitoring 
(CGM) systems that enable automated glucose sensing 
from the interstitial compartment constitute convenient 
therapeutic aids that reduce the drawbacks of self- blood 
glucose monitoring during exercise. Indeed, integration 
of these devices during prolonged endurance exercise 
has proven successful in assisting glucose management via 
early identification of aberrations in glucose.5 7 10 12 14 18 A 
recent international consensus statement has advocated 
clinical thresholds that stratify glycemia into distinct 
target ranges,19 that is, time spent (%) below range (level 
2 (L2): <54 mg/dL; level 1 (L1): 54–69 mg/dL), time in 
range (TIR; 70–180 mg/dL) and time above range (TAR; 
L1: 181–250 mg/dL; L2: >250 mg/dL). These data can 
be mapped against insulin administration and mealtime 
feeding to help inform individualized treatment deci-
sions and facilitate glycemic control.20 However, we know 
little about the suitability and relevance of these thresh-
olds for professional athletes undergoing daily bouts of 
prolonged and strenuous exercise. Intriguingly, although 
the physiological needs and/or demands of these events 
have been documented within the literature,2 10 21 we 
know less about the real- time glycemic responses to 
their participation and the consequential impact they 
may have on postexercise and nocturnal glucose trends. 
Despite the challenges of controlling glycemia in active 
people with T1D, elite cyclists like those in Team Novo 
Nordisk demonstrate that high- end athletic performance 
in world- class Union Cycliste Internationale cycle events 
is possible. This presents a novel window to systematically 
observe CGM- derived glycemic patterns of athletes with 
T1D undergoing prolonged, strenuous exercise sessions 
as part of an intense preseason training camp.
Aim
This prospective observational study sought to establish 
the glycemic, physiological and dietary demands of stren-
uous exercise training as part of a 9- day performance 
camp in a professional cycling team with T1D.
MATeRIAls And MeTHods
study design
This was an observational study.
Participant characteristics
Sixteen male cyclists with T1D from one professional 
cycling team volunteered to participate in this research 
study. All participants were provided with a full descrip-
tion of the study and signed an informed consent form 
prior to the start of any testing. The anthropometric 
and diabetes characteristics of all 16 participants are 
presented in table 1. The physiological responses to the 
cardiopulmonary exercise (CPX) testing to volitional 
exhaustion are also detailed in table 1. One cyclist was 
withdrawn from this test due to health issues.
Participants’ insulin regimen
All riders were on a stable multiple daily dose regimen 
consisting of a range of rapid- acting/short- lasting 
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and long- lasting insulin (bolus: n=6 Fiasp, n=9 Novo-
Rapid, n=1 Apidra; basal: n=10 Lantus, n=4 Levemir, 
n=2 Toujeo). Of the 16 riders, 13 took basal insulin 
in the evening while 3 riders were on a bidaily basal 
regimen. Cyclists’ self- reported total insulin doses ranged 
between 24±14 (minimum) and 28±15 (maximum) IU 
daily, consisting of a bolus of 11±4 (minimum) to 12±4 
(maximum) IU daily, and basal of 13±10 (minimum) to 
16±12 (maximum) IU daily.
Cycle training regimen
Riders performed eight training rides over 9 days lasting 
between 2 and 6 hours, traversing 56–183 km/day at 
60%–75% maximum heart rate (HR), with 1 day dedi-
cated to CPX testing (day 6). Participants performed all 
race stages on an individual time- trial basis with a mobile 
power meter (Pioneer, USA) and with a cycle computer 
(Wahoo, Wahoo Fitness, USA) mounted on their bike 
which allowed the monitoring, with a frequency of 
1 Hz, of power output (W), cadence (revolutions per 
minute (rpm)), temperature (°C), speed (km/hour), 
elevation (m), grade (%) and daily racing regimen (ie, 
distance (km), duration (hours), elevation gain (m), 
energy expenditure (kcal)). Riders were instructed to 
perform zero- offset procedures prior to each training 
session according to manufacturers’ instruction. HR 
was measured during every race using a portable chest 
strap (Garmin, USA). Cycle training metrics (time, 
speed, power, gradient, temperature, HR) were logged 
using Elemnt headset devices (Wahoo GPS cycle units) 
for later uploading via the Training Peaks computerized 
cloud- based package (Training Peaks, USA). A detailed 
overview of training- based metrics can be found in online 
supplementary file 1.2.
Cardiopulmonary cycle exercise testing
On day 6 of the training camp, cyclists performed an 
incremental CPX test on their personal bicycle (Colnago 
C60) attached to a cycle trainer (KICKR, Wahoo, USA). 
After a standardized warm- up phase, participants began 
testing at a fixed rate of 100 W with consequent workload 
increase of 10 W (Ergometer (ERG) mode) every minute 
until volitional exhaustion. Volitional exhaustion was 
defined as an inability to maintain a cadence ≥50 rpm for 
5 s. During exercise, pulmonary gas exchange (MetaMax 
3B; Cortex Biophysik, Leipzig, Germany) and HR (s810i, 
Polar Electro, Finland) were recorded continuously and 
subsequently averaged every 5 s. Ratings of perceived 
exertion (Borg Scale22) and earlobe capillary blood 
lactate and glucose sampling (Biosen C- Line, EKF Diag-
nostics, Germany) were performed at rest and after each 
exercise stage.
Continuous glucose monitoring
Riders were provided with unblinded subcutaneous 
glucose monitoring systems (Dexcom G6, USA) for 
the duration of the study. A self- inserted subcutaneous 
glucose sensor was wirelessly connected to a glucose 
reader (Dexcom, USA). The water- resistant sensor was 
factory- calibrated with a shelf- life of 10 days. Data were 
downloaded for later export and analysis.
nutritional tracking and macronutrient reporting
Over the 9- day training camp, a registered dietitian and 
team physician provided daily printed dietary plans for 
each meal. Each structured meal plan included a list 
of available food items and serving suggestion based 
on bodyweight. Food scales were provided at each 
meal sitting and riders were encouraged to use them 
to match meal plan amounts. Carbohydrate (CHO, g), 
protein (g), fat (g) and total energy (kcal) information 
was included in each document to guide individual-
ized insulin doses. During exercise, dietary intake was 
recorded via the provision of individualized rider feed 
bags. Each bag contained a fixed amount of food items 
for which the nutrient composition was acquired directly 
from the product labels. Immediately after the ride, bags 
were returned, and the contents were analyzed by the 
research team. Quantities were then verified with each 
rider independently via social media text messages and 
verbal confirmation when necessary.
data analysis
All statistical analyses were carried out using SPSS V.26.0 
statistical software, and p≤0.05 (two- tailed) was consid-
ered statistically significant. Unless stated otherwise, all 
data are presented as mean±SD. Relationships between 
variables were assessed using general linear regression. 
Between camp day differences were assessed by means 
of analysis of variance, while paired sampled t- tests were 
used to explore diurnal differences. A two- by- two cross- 
tabulation analysis of nominally coded variables (hypo-
glycemia occurrence) was used to determine estimated 
risk ratios (ERR), with Fisher’s exact test used to report p 
values and Cramer’s V scores to demonstrate the strength 
of relationship. CGM data were downloaded from 
the online Clarity platform for each rider over a 9- day 
period and grouped into day (06:00–23:59) or night 
(00:00–05:59) period. Per cent coverage was determined 
as the recorded number of data points divided by the 
maximum number of 5 min sample points within a time 
period. CGM from one rider was excluded for consent 
reasons. CGM data were stratified into time spent (%) 
into predefined glycemic ranges in accordance with a 
recent international consensus statement.19 Data were 
grouped into L2 hypoglycemia (<54 mg/dL), L1 hypogly-
cemia (≥54 to ≤69 mg/dL), euglycemia (≥70 to ≤180 mg/
dL), L1 hyperglycemia (≥181 to ≤250 mg/dL) and L2 
hyperglycemia (>250 mg/dL).
ResulTs
overall energy intake and macronutrient composition
A day- by- day breakdown of rider energy intake and macro-
nutrient composition can be found in online supple-
mentary file 1.1. On average, cyclists’ diet comprised 
63%±8% CHO, 15%±3% protein and 22%±8% fat. Inride 
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Table 2 Inexercise energy intake across each day of the 9- day training camp
Inexercise energy intake
Ride number
Ride duration 
(hours) Energy (kcal/hour) CHO (g/hour) Fat (g/hour) Protein (g/hour)
Day 1 4.2±0.1 163±93 35±21 2±1† 2±1‡
Day 2 5.5±1.4 287±288* 60±65* 5±4*† 3±1
Day 3 2.0±0.4 90±102* 20±20* 1±3* 1±1‡
Day 4 5.8±0.6 222±60 45±14 4±1 3±1
Day 5 3.6±0.3 264±111* 54±23 4±2 4±3‡
Day 6 CPX testing
Day 7 3.3±1.2 149±142 30±25 3±4 2±2‡
Day 8 4.7±0.6 238±79 48±15 4±2* 3±2
Day 9 5.9±0.2 261±93* 55±21* 4±2 2±1
Overall 4.3±1.5 209±149 44±32 3±3 2±2
P value <0.001 0.002 0.002 0.004 <0.001
Dietary data were not collected on day 6 due to CPX testing.
Data are presented as mean±SD and expressed as intake per hour per kilogram of body mass. N=16.
*P≤0.05 between day 3 and all other identified trials.
†P≤0.05 between day 2 and all other identified trials.
‡P≤0.05 between day 5 and all other identified trials.
CHO, carbohydrate; CPX, cardiopulmonary exercise.
nutrient consumption ranged from 12% to 25% of the 
total daily energy intake. Considerably more calories were 
consumed on day 9 versus all other days (p≤0.001; kcal). 
Similarly, more CHO were consumed on day 9 compared 
with all other days bar day 2 (p≤0.009; CHO*). However, 
day 2 did differ from days 1 (p=0.004), 3 (p=0.012) and 
7 (p<0.001; CHO). Both total energy (β=0.348, p<0.001) 
and CHO (β=0.186, p=0.027) intake increased linearly 
alongside camp duration. Protein intake was lowest on 
the first day of training camp and differed from the later 
3 days of camp (p<0.001; Pro). With the exception of day 
2 (which differed from days 1, 3, 4, 5 and 6; Pro), protein 
intake also increased with camp duration (β=0.375, 
p<0.001). Although the same was true for fat intake (day 
1 lowest value compared with days 2, 3, 5, 7, 8 and 9; 
p≤0.008; fat), fat consumption was lower on day 6 (CPX 
testing with no formal training ride) compared with most 
other days (days 2, 3, 5, 7 and 8; p≤0.003; fat) and failed 
to demonstrate significant signs of a linear relationship 
with camp duration (β=0.106, p=0.213).
Inexercise energy intake and macronutrient composition
A descriptive table of energy intake and macronutrient 
composition during exercise is shown in table 2.
Analysis of mean nutrition data over the training camp 
revealed cyclists’ energy consumption was 209±149 kcal/
hour, consisting of 44±32 g/hour (77%) CHO, 3±3 g/
hour (13%) fat, and 2±1 g/hour (10%) protein. Day- 
by- day analysis revealed significantly more energy was 
consumed on day 3 versus days 2 (p=0.005), 5 (p=0.024) 
and 9 (p=0.036; kcal). Further macronutrient analysis 
indicated that this calorie deficit was accounted for 
by lesser amounts of CHO on day 3 versus both days 
2 (p=0.010) and 9 (p=0.049; CHO). Similarly, less fat 
was consumed on day 3 versus days 2 (p=0.011) and 8 
(p=0.023; fat), but also on day 2 versus day 1 (p=0.050; 
fat). Finally, more protein was consumed on day 5 versus 
days 1 (p=0.014), 3 (p<0.001) and 7 (p=0.001; Pro).
Figure 1 illustrates the relationships between exer-
cise length and inride energy intake. Cycle duration 
was related to total energy (β=0.679, p<0.001), CHO 
(β=0.660, p<0.001), fat (β=0.601, p<0.001) and protein 
intake (β=0.497, p<0.001).
However, no macronutrient explained the variance 
in inride interstitial glucose (iG) concentration. Simi-
larly, the time spent in each glycemic range during the 
nocturnal hours that preceded next- day cycle sessions 
had no impact on inride dietary intake.
exercise physiological responses to cycle training sessions
The physical and physiological responses to cycle training 
sessions are reported in online supplementary file 1.2 and 
table 2. Cycle distance ranged from 56 to 183 km/day, with 
a duration of 4.3±1.4 hours per session. The mean power 
output was approximately 50% of the peak aerobic power 
obtained during the cardiopulmonary cycle test. The 
maximum power elicited during cycle training sessions 
was twice that of the peak aerobic power during the 
CPX test. The mean cycle HR (131±11 beats per minute 
(bpm)) was 70% of the maximum values (189±10 bpm). 
The peak HR obtained during cycle training was 91% of 
that obtained at the end of the cardiopulmonary cycle 
test. Cycle training sessions consisted of most time spent 
in HR zones 1–3 (please refer to online supplementary 
file 1.2).
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Figure 1 Cycle duration as it relates to total energy (A), carbohydrate (CHO) (B), fat (C) and protein (D) intake.
Glycemic data
Overall glycemia during training camp
Continuous iG profiles from the 24 hours over 9 days 
revealed that riders spent 76% of time in euglycemia, 
18% of time in hyperglycemia (L1: 15; L2: 3%) and 6% 
of time in hypoglycemia (L1: 4; L2: 2%). CGM was active 
80%±13% of time over the 9 days of data collection and 
did not differ between daytime and night- time periods 
(day 78%±17% vs night 82%±10%, p=0.424).
Day-by-day glycemic variance during training camp
A graphical illustration of the mean iG for each day and 
night and overall can be found in online supplementary 
file 1.3. There was no difference between camp days in 
either the daytime (p=0.263) or night- time (p=0.497) 
mean glucose concentrations. The time spent in different 
glycemic ranges stratified into day (06:00–23:59), 
night (00:00–05:59) and exercise- only time periods are 
presented in figure 2.
During the day- time periods, there was no difference in 
the amount of time spent in hypoglycemia (L2; p=0.65, 
L1; p=0.86), euglycemia (p=0.93) or L1 hyperglycemia 
(p=0.96). However, camp days differed in the amount of 
time spent in L2 hyperglycemia (p=0.01). Although pair-
wise comparisons failed to identify the source of signifi-
cance, it appeared to be driven by a greater amount of 
time spent in L2 hyperglycemia on day 2 versus day 7 (day 
2: 1% vs day 7: 5%, p=0.084).
There was no difference between nights in the amount 
of time spent in either hypoglycemia (L2; p=0.88, 
L1; p=0.73) or L2 hyperglycemia (p=0.89). However, 
nocturnal periods differed in the amount of time spent 
in both euglycemia (p=0.05) and L1 hyperglycemia 
(p=0.05). Although pairwise analysis failed to exact 
significance, the greatest difference was between night 6 
and night 9 (euglycemia night 6: 90% vs night 9: 59%, 
p=0.215; L1 hyperglycemia night 6: 4% vs night 9: 27%, 
p=0.233).
Day versus night iG patterns
Overall, there was no difference between the mean day 
iG compared with night (day 138±25 mg/dL vs night 
135±44 mg/dL, p=0.421). The SD of iG was greater 
during daytime than night- time hours (day 43±16 mg/dL 
vs night 25±20 mg/dL, p<0.001). Coefficient of variation 
(%) in data was also higher during the daytime period 
(day 31%±10% vs night 19%±13%, p<0.001). Although 
the average peak glucose concentration was higher 
during the day versus the night hours (day 211±58 mg/
dL vs night 178±61 mg/dL, p<0.001), the minimum value 
was similar (day 89±29 mg/dL vs night 94±37 mg/dL, 
p=0.095).
When separated into daytime and night- time periods, 
there was no difference in the time spent below target 
(L1 and L2) during the nocturnal hours (night 8% vs day 
6%, p=0.155). While there were also no differences when 
data were stratified into L1 and L2 ranges, there was a 
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Figure 2 Time spent in different glycemic ranges split into day (06:00–23:59), night (00:00–05:59) and exercise- only time 
periods (%, mean±SD, n=15). P values represent the difference between camp days in time spent in each glycemic threshold. 
Dark blue segment on pie chart represents time spent (%) in level 2 hypoglycemia (<54 mg/dL). Orange segment on pie chart 
represents time spent (%) in L1 hypoglycemia (≥54 to ≤69 mg/dL). White segment on pie chart represents time spent (%) in 
euglycemia (≥70 to ≤180 mg/dL). Yellow segment on pie chart represents time spent (%) in L1 hyperglycemia (≥181 to ≤250 mg/
dL). Light blue segment on pie chart represents time spent (%) in L2 hyperglycemia (>250 mg/dL). Eu, euglycemia; Hyper, 
hyperglycemia; Hypo, hypoglycemia; L1, level 1; L2, level 2.
trend for increased time spent in L1 hypoglycemia during 
the night- time (L1 night 5.6%±12.8% vs day 3.6%±5.2%, 
p=0.080; L2 night 2.4%±7.4% vs day 2.0%±9.9%, p=0.666). 
There were no differences between daytime and night- 
time spent in euglycemia (night 74.3%±29.3% vs day 
75.7%±17.6%, p=0.602) and in L1 (night 13.6%±21.7% vs 
day 15.9%±14.2%, p=0.260) or L2 (night 4.1%±11.6% vs 
day 2.8%±4.2%, p=0.284) hyperglycemia.
A greater amount of time spent in nocturnal hypo-
glycemia was related to a greater amount of time spent 
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below target range the following day (β=0.265, p=0.003). 
Furthermore, the occurrence of nocturnal hypoglycemia 
was associated with a 3.6- fold increase in risk of experi-
encing next- day hypoglycemia (ERR 3.641 (95% CI 1.589 
to 8.345), p<0.001, Cramer’s V=0.360).
Glycemic responses to cycle training sessions
The time spent in euglycemia ranged from 69.4% to 
85.3% across different training days. The mean iG was 
140±42 mg/dL, ranging from the lowest recorded value 
of 46 mg/dL to a peak concentration of 331 mg/dL. The 
mean iG was negatively correlated to the occurrence of L2 
(r=−0.271, p=0.010) and L1 (r=−0.410, p<0.001) hypogly-
cemia, and positively correlated to the occurrence of both 
L1 (r=0.769, p<0.001) and L2 hyperglycemia (r=0.665, 
p<0.001). There was no difference between rides in the 
amount of time spent in either eu- (p=0.60) or hyper- 
glycemia (L1; p=0.51, L2; p=0.27). There was a signifi-
cant difference between cycle sessions in the amount of 
time spent in both L2 (p=0.04) and L1 (p=0.03) hypo-
glycemia over the training camp. Further analysis iden-
tified that day 3 was associated with more time spent 
in L2 hypoglycemia than days 4 (p=0.060), 5 (p=0.035) 
and 6 (p=0.074). Similarly, day 3 had higher levels of L1 
hypoglycemia than days 4 (p=0.048), 5 (p=0.050) and 7 
(p=0.070). A greater time spent in hypoglycemia during 
the night- time period was associated with a higher preva-
lence of next- day hypoglycemia during cycling (β=0.252, 
p=0.019). Nocturnal hypoglycemia was associated with 
a 1.8- fold increase in the risk of next- day inride hypo-
glycemia (ERR 1.797 (95% CI 1.22 to 2.634), p<0.001, 
Cramer’s V=0.484).
dIsCussIon
This study was the first to establish the glycemic, phys-
iological and dietary demands of strenuous exercise 
training as part of a 9- day performance camp in a profes-
sional cycling team with T1D. Cyclists with T1D main-
tained a large proportion of time in a euglycemic range 
and fell within clinical recommendations. However, we 
have demonstrated that antecedent hypoglycemia in the 
nocturnal hours that preceded next- day cycling was asso-
ciated with over three times the risk of next- day hypogly-
cemia and a 1.8- fold increase in the risk of experiencing 
hypoglycemia while cycling.
24-hour glycemia
Twenty- four- hour glycemic data generated over the 9- day 
training camp demonstrated revealing insights of profes-
sional cyclists with T1D engaged in intense exercise. Clin-
ical recommendations endorsed by several international 
diabetes associations, foundations and societies estab-
lished adult iG targets to attain <5% of TIR at L2 hyper-
glycemia, <25% L1 hyperglycemia, >70% TIR, <4% L1 
hypoglycemia and <1% L2 hypoglycemia, respectively.19 
Our data demonstrate cyclists spent 3% of time with L2 
hyperglycemia, 15% with L1 hyperglycemia, 76% TIR, 
4% L1 hypoglycemia and 2% L2 hypoglycemia, respec-
tively. These data inform several discussion points. The 
time spent in euglycemia (76%) was categorized as ‘very 
good’ against current clinical recommendations19 and 
commendable for a team of cyclists riding on average 
4.3 hours and consuming ~5000 kcal each day. Such 
intense demands of cycling (in which the rate of glucose 
combustion is markedly increased over the rest values) 
and large macronutrient intake may account for the large 
coefficient of variation in riders’ data (36%–38% coeffi-
cient of variation). A lower time spent in hyperglycemia 
(L1 and L2: 18%) is admirable and falls within the <30% 
value recommended for individuals with diabetes.19 
However, although time spent in L1 hypoglycemia was 
acceptable, the amount spent in L2 hypoglycemia was 
twice that recommended by clinical guidelines (2% vs 
1%). Tempering this 1% higher rate of L2 hypoglycemia 
may be a challenge given the inherent physical demands 
of professional cycling, but technological advancements 
around monitoring of glucose, insulin and food intake 
may aid in the implementation of more refined, rapid 
and individualized strategies that collectively contribute 
to a reduction in this value.
Our observations revealed a tendency for greater 
nocturnal hypoglycemia compared with daytime. That 
the riders were in a daily postexercise insulin- sensitized 
state, administered basal insulin in the evening, and may 
not have eaten for 2–3 hours before bed may create an 
environment where nocturnal hypoglycemia is more 
frequent. Indeed, an interesting observation was greater 
nocturnal hypoglycemia in the first 2 days of training 
and might suggest an early maladaptive response to the 
4.2- hour and 5.5- hour cycle rides. More attention to 
managing this occurrence might focus on late prebed 
feeding or adjustments in insulin administration strate-
gies.23 A limitation of our study was the inability to monitor 
cyclists’ insulin administration strategies, but reductions 
in basal and/or bolus insulin have been demonstrated to 
improve postexercise and glycemia observationally and 
in laboratory- controlled studies.2 3 8 10 11 15 18 24 It should 
be noted that rider monitoring is difficult in the early 
morning hours when asleep, and although glycemic 
threshold alarms are possible on CGM devices alarm 
threshold settings are highly individualized and balanced 
between being too high to facilitate sleep or too low to 
prevent a hypoglycemic event from occurring.
Inride glycemia and nutritional intake
Despite the long duration of most of the cycle rides, the 
mean iG was euglycemic during each cycle ride. The 
mean iG during cycling was negatively correlated to the 
occurrence of L2 hypoglycemia (r=−0.227, p=0.043) and 
positively correlated to the occurrence of L1 (r=0.234, 
p=0.037) hyperglycemia, thus presenting an indicator 
of the importance of supporting glycemia in the upper 
boundaries of ‘euglycemia’ during cycling. These data 
might suggest a case for additional CHO to support 
glucose concentrations within the higher end of the 
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euglycemic range, without compromising time spent in 
hyperglycemia but with the added benefit of available 
energy for combustion to power cycling performance. 
We also demonstrated that antecedent hypoglycemia in 
the nocturnal hours that precede next- day cycle exercise 
was associated with a greater risk of inexercise hypogly-
cemia. It is well known that antecedent hypoglycemia 
influences the counter- regulatory hormone response to 
exercise.25 26 Additionally, subsequent episodes of hypo-
glycemia can exacerbate the blunted responses to latent 
hypoglycemia and ultimately further perpetuate the like-
lihood of repeat hypoglycemia. 27
Inride macronutrient analysis revealed high relative 
CHO proportions (77%), with fat (13%) and protein 
(10%), accounting for the remainder of dietary intake 
during rides. Cyclists consumed between 13% and 25% 
of their total daily energy intake on the bike, and this was 
dependent on ride duration. However, when the rate of 
CHO intake (CHO g/hour) was grouped according to 
the length of cycle sessions, we found cyclists consumed 
CHO at a rate of 20–30 g/hour for a ride of 2–3 hours, 
35–53 g CHO/hour between 3.5- hour and 4.5- hour 
cycle, and 45–58 g CHO/hour on rides lasting between 
4.5 and 6.0 hours. This differs markedly from general 
recommendations for endurance athletes of 60 g/hour 
for exercise lasting 2–3 hours and 90 g/hour for event 
duration >3 hours. 28 29 Although whether or not these 
guidelines are realistic has recently been questioned, 
with research detailing that athletes often fail to attain 
these targets during long distance events.30 31 In our 
data, a possible explanation for the shortfall may be the 
tendency of riders to consume a large breakfast prior 
to cycling (estimated calorie intake during this meal 
ranged between 900 and 1700 kcal and represented 
~25% of the total daily nutrient intake); CHO intake 
rate still appears low compared with recommendations 
for athletic individuals without diabetes. As iterated 
above, it is interesting to speculate on the potential for 
practicing greater CHO ingestion (of a low glycemic 
index) to benefit sprints or end of stage racing while 
optimizing glycemic management. Furthermore, these 
data provide an initial platform from which individ-
ualized dietary plans can be implemented to ensure 
adequate fuel provision at a rate that is not only depen-
dent on the absolute exercise intensity, but also the 
duration of the event.
Finally, as most cyclists took evening basal Lantus or 
split Levemir alongside relatively small amounts of bolus 
insulin, riders may have had relatively low circulating 
insulin concentrations during cycling. From an exercise 
performance perspective, higher concentrations of circu-
lating exogenous insulin during cycling, concomitant 
with a stronger counter- regulatory hormone response to 
the exercise stimulus, may facilitate an increase in local-
ized intramuscular glucose uptake. Thus, although the 
cost of this in terms of variance in glycemia is not known, 
experimentation in pre- exercise and postexercise meal-
time individualized insulin to CHO ratios may translate 
to improved exercise performance and/or recovery 
outcomes.
ConClusIons
This study demonstrated that professional cyclists with 
T1D maintained a large proportion of time in a eugly-
cemic range over a 9- day intensified cycle training 
period. However, there was a tendency for higher levels 
of nocturnal hypoglycemia, which led to an increased 
risk of next- day hypoglycemia and a consequential 
impact on glucose during cycling training sessions. The 
potential long- lasting, insulin- sensitizing effects of endur-
ance cycling illustrates a need for intensive monitoring 
of riders and dynamic, individualized glycemic manage-
ment strategies. These data provide a foundation for the 
development of individualized nutritional, physiological 
and therapeutic strategies that may assist in improving 
exercise performance through glycemic optimization in 
elite cyclists with T1D.
study strengths, limitations and future recommendations
This study is the first to systematically detail the glycemic 
effects of strenuous cycle training as part of a performance 
training camp in professional cyclists with T1D. Access to 
a combination of power meter data, inride nutrition and 
CGM in 16 professional cyclists with T1D has enabled a 
growth in our understanding of the demands of exercise 
performance at a world- class level. Given our population 
cohort, a clear limitation was the lack of detailed infor-
mation on exogenous insulin analog administration over 
the course of camp. It should also be noted that CGM 
data were collated over a 9- day timeframe and thus fall 
slightly below the 2- week period referenced for adequate 
coverage guidelines. Future research would benefit from 
investigating the potential glycemic implications of exog-
enous basal- bolus insulin dosing strategies around intense 
exercise training, so as to improve our understanding of 
the physiological, nutritional and therapeutic demands 
of elite performance in athletes with T1D.
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